Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

Clinical trial NCT04137900 · UNKNOWN

Trial details

NCT number: NCT04137900
Sponsor: TopAlliance Biosciences
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Unresectable Solid Tumor Metastatic Solid Tumor

Start date: 2019-10-30
Primary completion: 2026-03-01
Enrollment: 499

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.